 2021 Earnings Call Summary: Labcorp

Labcorp reported strong results in the third quarter of 2021, with revenue totaling $4.1 billion, adjusted earnings per share reaching $6.82, and free cash flow of $650 million. The company's Base Business for both Diagnostics and Drug Development performed well, with 10% and 22% growth, respectively. COVID testing volumes were above the same period last year, with time to results averaging one to two days. Labcorp continues to support the fight against the pandemic through both its diagnostic and drug development capabilities. The company recently received Emergency Use Authorization for a combined COVID and flu-at-home collection kit and collaborated with AstraZeneca on a COVID prevention and treatment trial. Labcorp is also working on bringing new innovations to market, such as a combined COVID and flu-at-home collection kit and collaborating with Merck on a COVID treatment trial. The company's strategy includes addressing health equity issues and partnering with Community Clinical Oncology Research. Labcorp is raising full year guidance for revenue, adjusted earnings per share, and free cash flow based on its strong third quarter performance and improved outlook for the remainder of the year.